Clinical trial
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus…
NCT00056446 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00056446 |
|---|---|
| Title | Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer |
| Official title | A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms |
| Intervention type | Drug |
| Interventions | Vatalanib |
| Enrollment | 855 |
| Start date | Jan 1, 2003 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Mar 14, 2003 |
| Last update posted | Mar 6, 2017 |
| Countries | Australia, Austria, Belgium, Brazil, Canada, France, Germany, Hong Kong, Italy, New Zealand, Portugal, Slovakia and 6 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: